On July 9, BridgeBio Pharma rose 5.31% in pre-market trading, trading at $82.10 per share with turnover of $74,800.
The move follows the company's completion of a $1 billion convertible preferred equity financing led by Sixth Street Partners ($800 million) and KKR. The funds will accelerate commercialization of three core rare disease candidates: BBP-418 for limb-girdle muscular dystrophy, encaleret for autosomal dominant hypocalcemia type 1, and infigratinib for achondroplasia. The initial conversion price of approximately $138 per share represents a 100% premium over the 30-day average, signaling strong investor confidence in the company's valuation.
On the pipeline front, infigratinib's Phase 3 Propel 3 trial data was published in the New England Journal of Medicine in late June after meeting its primary endpoint. BBP-418's NDA has been accepted by the FDA for priority review, while encaleret's NDA was submitted in May targeting a U.S. launch in early next year. The company is transitioning from a clinical-stage platform to a multi-product commercial entity.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
